TRCT
LMAT icon

Tower Research Capital (TRC)’s LeMaitre Vascular LMAT Stock Holding History

Tower Research Capital (TRC)’s Portfolio LMAT Stock Details LMAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$89.1K Buy
816
+256
+46% +$24.4K ﹤0.01% 2274
2025
Q4 		$45.4K Sell
560
-515
-48% -$44.3K ﹤0.01% 2495
2025
Q3 		$94.1K Sell
1,075
-661
-38% -$59K ﹤0.01% 2036
2025
Q2 		$144K Buy
1,736
+1,388
+399% +$116K ﹤0.01% 2081
2025
Q1 		$29.2K Sell
348
-4,298
-93% -$400K ﹤0.01% 2639
2024
Q4 		$428K Buy
4,646
+3,538
+319% +$340K 0.01% 1174
2024
Q3 		$103K Sell
1,108
-3,498
-76% -$303K ﹤0.01% 2212
2024
Q2 		$379K Buy
4,606
+4,194
+1,018% +$308K 0.01% 1565
2024
Q1 		$27.3K Sell
412
-13,935
-97% -$860K ﹤0.01% 2726
2023
Q4 		$814K Buy
14,347
+13,591
+1,798% +$712K 0.01% 999
2023
Q3 		$41.2K Sell
756
-1,722
-69% -$102K ﹤0.01% 2709
2023
Q2 		$167K Buy
2,478
+1,124
+83% +$68.6K 0.01% 1685
2023
Q1 		$70K Buy
1,354
+957
+241% +$46.5K ﹤0.01% 2200
2022
Q4 		$18K Sell
397
-6,675
-94% -$313K ﹤0.01% 3220
2022
Q3 		$358K Buy
7,072
+6,018
+571% +$301K 0.01% 1408
2022
Q2 		$48K Buy
1,054
+862
+449% +$38.6K ﹤0.01% 2926
2022
Q1 		$9K Sell
192
-198
-51% -$8.86K ﹤0.01% 4468
2021
Q4 		$20K Sell
390
-3,057
-89% -$158K ﹤0.01% 3665
2021
Q3 		$183K Sell
3,447
-6,468
-65% -$364K ﹤0.01% 1898
2021
Q2 		$605K Buy
9,915
+8,203
+479% +$436K 0.02% 1028
2021
Q1 		$84K Sell
1,712
-401
-19% -$18.8K ﹤0.01% 2721
2020
Q4 		$86K Sell
2,113
-14,561
-87% -$520K ﹤0.01% 2500
2020
Q3 		$542K Buy
16,674
+13,737
+468% +$412K 0.01% 1595
2020
Q2 		$78K Buy
+2,937
New +$76.8K ﹤0.01% 2675
2019
Q4 		– Sell
-82
Closed -$3K – 4004
2019
Q3 		$3K Sell
82
-278
-77% -$8.88K ﹤0.01% 3566
2019
Q2 		$10K Buy
360
+29
+9% +$806 ﹤0.01% 2564
2019
Q1 		$10K Buy
+331
New +$8.83K ﹤0.01% 2680
2018
Q3 		– Sell
-4,451
Closed -$149K – 4037
2018
Q2 		$149K Buy
4,451
+3,072
+223% +$109K 0.01% 1203
2018
Q1 		$50K Buy
+1,379
New +$47.8K ﹤0.01% 1674
2017
Q4 		– Sell
-1,981
Closed -$74K – 3786
2017
Q3 		$74K Buy
+1,981
New +$67.4K 0.01% 1627
2017
Q2 		– Sell
-100
Closed -$2K – 3123
2017
Q1 		$2K Buy
+100
New +$2.35K ﹤0.01% 2631
2016
Q3 		– Sell
-1,200
Closed -$17K – 4072
2016
Q2 		$17K Buy
+1,200
New +$18.3K ﹤0.01% 2381
2016
Q1 		– Sell
-345
Closed -$6K – 4579
2015
Q4 		$6K Sell
345
-2,759
-89% -$39.9K ﹤0.01% 2778
2015
Q3 		$37K Buy
+3,104
New +$39.8K ﹤0.01% 1239
2015
Q2 		– Sell
-63
Closed -$1K – 4753
2015
Q1 		$1K Buy
63
+31
+97% +$243 ﹤0.01% 4077
2014
Q4 		$0 Sell
32
-193
-86% -$1.38K ﹤0.01% 4375
2014
Q3 		$2K Buy
225
+125
+125% +$934 ﹤0.01% 3817
2014
Q2 		$1K Sell
100
-1,156
-92% -$9.04K ﹤0.01% 3689
2014
Q1 		$10K Buy
1,256
+1,056
+528% +$8.45K ﹤0.01% 2605
2013
Q4 		$2K Sell
200
-572
-74% -$4.42K ﹤0.01% 4018
2013
Q3 		$5K Buy
772
+700
+972% +$4.74K ﹤0.01% 3656
2013
Q2 		$0 Buy
+72
New +$454 ﹤0.01% 3951

Other funds holding LMAT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Tower Research Capital (TRC)'s LMAT Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its LeMaitre Vascular (LMAT) stake by 46% in Q1 2026, buying an estimated $24.4K and bringing the position to 816 shares worth $89.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2274.

Tower Research Capital (TRC) first reported a position in LMAT in Q2 2013 and has held it in 42 quarters since. The position peaked at $814K in Q4 2023. 339 funds tracked by Wall St. Rank hold LMAT as of Q1 2026.

  • Tower Research Capital (TRC) held 816 shares of LeMaitre Vascular worth $89.1K as of Q1 2026.
  • Tower Research Capital (TRC) bought 256 LeMaitre Vascular shares in Q1 2026, an estimated $24.4K.
  • LeMaitre Vascular made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2274 holding.
  • Tower Research Capital (TRC) first reported a position in LeMaitre Vascular in Q2 2013 and has held it in 42 quarters since.
  • Tower Research Capital (TRC)'s LeMaitre Vascular position peaked at $814K in Q4 2023.
  • 339 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.